CanSino Biologics (SHSE:688185) Debt-to-Revenue : 4.63 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

CanSino Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥955.0 Mil. CanSino Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,162.7 Mil. CanSino Biologics's annualized Revenue for the quarter that ended in Mar. 2024 was ¥457.1 Mil. CanSino Biologics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 4.63.

CanSino Biologics Debt-to-Revenue Historical Data

The historical data trend for CanSino Biologics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Debt-to-Revenue Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

7.69

0.32

2.62

7.82

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial													-	N/A	3.20	3.98	4.63

Competitive Comparison of CanSino Biologics's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CanSino Biologics's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Debt-to-Revenue falls into.

CanSino Biologics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

CanSino Biologics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1459.498	+	1240.843)	/	345.182
	=	7.82

CanSino Biologics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(955.025	+	1162.688)	/	457.128
	=	4.63

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

CanSino Biologics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (SHSE:688185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

CASBF:USA 06185:Hong Kong CJH:Germany

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (SHSE:688185) Headlines

No Headlines